Evidence map›Paper›PMID 40184253›Full record

ArticleCell reports2025

A global collaboration for systematic analysis of broad-ranging antibodies against the SARS-CoV-2 spike protein.

Sharon L Schendel, Xiaoying Yu, Peter J Halfmann, Jarjapu Mahita, Brendan Ha, Kathryn M Hastie, Haoyang Li, Daniel Bedinger, Camille Troup, Kan Li and 37 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

47 authors.

Sharon L SchendelCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA 92037, USA.
Xiaoying YuCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA 92037, USA.
Peter J HalfmannInfluenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI 53711, USA.
Jarjapu MahitaCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA 92037, USA.
Brendan HaCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA 92037, USA.
Kathryn M HastieCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA 92037, USA.
Haoyang LiCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA 92037, USA.
Daniel BedingerCarterra, Inc., Salt Lake City, UT 84103, USA.
Camille TroupCarterra, Inc., Salt Lake City, UT 84103, USA.
Kan LiCenter for Human Systems Immunology, Departments of Surgery and Integrative Immunobiology, Duke University, Durham, NC 27701, USA.
Natalia KuzminaDepartment of Pathology, University of Texas Medical Branch at Galveston, 301 University Boulevard, Galveston, TX 77555, USA; Galveston National Laboratory, 301 University Boulevard, Galveston, TX 77550, USA.
Jordi B TorrellesDisease Intervention and Prevention and Population Health Programs, Texas Biomedical Research Institute, San Antonio, TX 78227, USA; Population Health Program, International Center for the Advancement of Research & Education (I-CARE), Texas Biomedical Research Institute, San Antonio, TX 78227, USA.
Jennifer E MuntDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27516, USA.
Melissa MattocksDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27516, USA.
Mary Osei-TwumNexelis, a Q2 Solutions Company, 525 Boulevard Cartier Ouest, Laval, QC H7V 3S8, Canada.
Heather M CallawayCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA 92037, USA.
CoVIC-DB TeamCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA 92037, USA.
Stephen ReeceKymab, a Sanofi Company, Babraham Research Campus, Cambridge CB22 3AT, UK.
Anne PalserRQ Biotechnology Ltd., London W12 7RZ, UK.
Paul KellamRQ Biotechnology Ltd., London W12 7RZ, UK; Department of Infectious Diseases, Faculty of Medicine, Imperial College, London SW7 2AZ, UK.
S Moses DennisonCenter for Human Systems Immunology, Departments of Surgery and Integrative Immunobiology, Duke University, Durham, NC 27701, USA.
Richard H C HuntworkCenter for Human Systems Immunology, Departments of Surgery and Integrative Immunobiology, Duke University, Durham, NC 27701, USA.
Gillian Q HornCenter for Human Systems Immunology, Departments of Surgery and Integrative Immunobiology, Duke University, Durham, NC 27701, USA.
Milite AbrahaCenter for Human Systems Immunology, Departments of Surgery and Integrative Immunobiology, Duke University, Durham, NC 27701, USA.
Elizabeth FeeneyCenter for Human Systems Immunology, Departments of Surgery and Integrative Immunobiology, Duke University, Durham, NC 27701, USA.
Luis Martinez-SobridoDisease Intervention and Prevention and Population Health Programs, Texas Biomedical Research Institute, San Antonio, TX 78227, USA; Population Health Program, International Center for the Advancement of Research & Education (I-CARE), Texas Biomedical Research Institute, San Antonio, TX 78227, USA.
Paula A PinoDisease Intervention and Prevention and Population Health Programs, Texas Biomedical Research Institute, San Antonio, TX 78227, USA.
Amberlee HicksDisease Intervention and Prevention and Population Health Programs, Texas Biomedical Research Institute, San Antonio, TX 78227, USA.
Chengjin YeDisease Intervention and Prevention and Population Health Programs, Texas Biomedical Research Institute, San Antonio, TX 78227, USA; Population Health Program, International Center for the Advancement of Research & Education (I-CARE), Texas Biomedical Research Institute, San Antonio, TX 78227, USA.
Jun-Gyu ParkDisease Intervention and Prevention and Population Health Programs, Texas Biomedical Research Institute, San Antonio, TX 78227, USA.
Billie MaingotDisease Intervention and Prevention and Population Health Programs, Texas Biomedical Research Institute, San Antonio, TX 78227, USA.
Sivakumar PeriasamyGalveston National Laboratory, 301 University Boulevard, Galveston, TX 77550, USA.
Michael MalloryDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27516, USA.
Trevor ScobeyDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27516, USA.
Marie-Noelle LepageNexelis, a Q2 Solutions Company, 525 Boulevard Cartier Ouest, Laval, QC H7V 3S8, Canada.
Natalie St-AmantNexelis, a Q2 Solutions Company, 525 Boulevard Cartier Ouest, Laval, QC H7V 3S8, Canada.
Sarwat KhanNexelis, a Q2 Solutions Company, 525 Boulevard Cartier Ouest, Laval, QC H7V 3S8, Canada.
Anaïs GambiezCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA 92037, USA.
Coronavirus Immunotherapeutic Consortium
Ralph S BaricPopulation Health Program, International Center for the Advancement of Research & Education (I-CARE), Texas Biomedical Research Institute, San Antonio, TX 78227, USA; Department of Microbiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Alexander BukreyevDepartment of Pathology, University of Texas Medical Branch at Galveston, 301 University Boulevard, Galveston, TX 77555, USA; Galveston National Laboratory, 301 University Boulevard, Galveston, TX 77550, USA; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA.
Luc GagnonNexelis, a Q2 Solutions Company, 525 Boulevard Cartier Ouest, Laval, QC H7V 3S8, Canada.
Timothy GermannCarterra, Inc., Salt Lake City, UT 84103, USA.
Yoshihiro KawaokaInfluenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI 53711, USA; Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan; The Research Center for Global Viral Diseases, National Center for Global Health and Medicine Research Institute, Tokyo 162-8655, Japan; Pandemic Preparedness, Infection and Advanced Research Center (UTOPIA), University of Tokyo, Tokyo 162-8655, Japan.
Georgia D TomarasCenter for Human Systems Immunology, Departments of Surgery and Integrative Immunobiology, Duke University, Durham, NC 27701, USA.
Bjoern PetersCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA 92037, USA; Department of Medicine, University of California, San Diego, La Jolla, CA 92037, USA. Electronic address: bpeters@lji.org.
Erica Ollmann SaphireCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA 92037, USA; Department of Medicine, University of California, San Diego, La Jolla, CA 92037, USA. Electronic address: erica@lji.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Coronavirus Immunotherapeutic Consortium (CoVIC) conducted side-by-side comparisons of over 400 anti-SARS-CoV-2 spike therapeutic antibody candidates contributed by large and small companies as well as academic groups on multiple continents. Nine reference labs analyzed antibody features, including in vivo protection in a mouse model of infection, spike protein affinity, high-resolution epitope binning, ACE-2 binding blockage, structures, and neutralization of pseudovirus and authentic virus infection, to build a publicly accessible dataset in the database CoVIC-DB. High-throughput, high-resolution binning of CoVIC antibodies defines a broad and predictive landscape of antibody epitopes on the SARS-CoV-2 spike protein and identifies features associated with durable potency against multiple SARS-CoV-2 variants of concern and high in vivo efficacy. Results of the CoVIC studies provide a guide for selecting effective and durable antibody therapeutics and for immunogen design as well as providing a framework for rapid response to future viral disease outbreaks.

Indexed as

Antibodies, ViralCOVID-19SARS-CoV-2Spike Glycoprotein, CoronavirusAngiotensin-Converting Enzyme 2AnimalsAntibodies, NeutralizingEpitopesHumansMiceAngiotensin-Converting Enzyme 2Antibodies, NeutralizingAntibodies, ViralEpitopesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2coronavirusCOVID-19CP: Immunologyhigh-resolution epitope binningneutralizationSARS-CoV-2 spike proteintherapeutic antibodies

Identifiers

PMID40184253
PMCPMC12014896

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.